Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.76 |
| ▸ | PLK1 | P53350 | 1/20 | 0.76 |
| ▸ | BACE1 | P56817 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | ELANE | P08246 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.73 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.73 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.67 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16894632 | 0.93 | ACHE (0.76) | ACHEPLK1BACE1ALDH1A1MAPT | |
| SCHEMBL7168992 | 0.89 | ALDH1A1 (0.68) | ALDH1A1MAPTCYP3A4MAPK1USP2 | |
| SCHEMBL6359647 | 0.89 | ACHE (0.81) | ACHEPLK1BACE1MAPTKDM4E | |
| SCHEMBL987761 | 0.88 | ALDH1A1 (0.78) | ACHEPLK1BACE1ALDH1A1MAPT | |
| SCHEMBL30235468 | 0.88 | ALDH1A1 (0.78) | ACHEPLK1BACE1ALDH1A1MAPT | |
| SCHEMBL29419950 | 0.88 | ALDH1A1 (0.78) | ACHEPLK1BACE1ALDH1A1MAPT | |
| SCHEMBL6365437 | 0.88 | ACHE (0.80) | ACHEPLK1BACE1ALDH1A1MAPT | |
| SCHEMBL30267770 | 0.87 | ACHE (0.75) | ACHEPLK1BACE1ALDH1A1MAPT | |
| SCHEMBL28985289 | 0.87 | ACHE (0.75) | ACHEPLK1BACE1ALDH1A1MAPT | |
| Moslosooflavone SCHEMBL29822243 | 0.86 | ACHE (1.00) | ACHEPLK1BACE1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118490702-A | Citrus extract and preparation method and application thereof | 浙江大学 | 2024-08-16 | — | — | CN | claimed |
| CN-118121649-A | Citrus extract, compound, and use thereof for inhibiting novel coronaviruses | 丰苗生物科技股份有限公司 | 2024-06-04 | — | — | CN | claimed |
| CN-109374762-B | Method for identifying citrus reticulata blanco and citrus reticulata blanco varieties based on metabonomics | 广州中医药大学第一附属医院 | 2021-10-08 | — | — | CN | claimed |
| US-20140039044-A1 | Hydroxylated Polymethoxyflavone Compositions | WLLGEN, INC. (US) | 2014-02-06 | — | — | US | claimed |
| JP-2009506057-A | — | — | 2009-02-12 | — | — | JP | claimed |
| EP-1928480-A2 | METHODS FOR MANAGING ADIPOCYTE FAT ACCUMULATION | Wellgen, Inc. (US) | 2008-06-11 | — | — | EP | claimed |
| US-20070275106-A1 | Hydroxylated polymethoxyflavone compositions | WELLGEN, INC. | 2007-11-29 | — | — | US | claimed |
| WO-2007083263-A1 | PROCESS TO PREPARE FLAVONES | FIRMENICH SA (CH) | 2007-07-26 | — | — | WO | claimed |
| US-20070088078-A1 | Methods for managing adipocyte fat accumulation | WELLGEN, INC. | 2007-04-19 | — | — | US | claimed |
| US-7201928-B1 | Extracts of orange peel for prevention and treatment of cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2007-04-10 | — | — | US | claimed |
| WO-2007024982-A2 | METHODS FOR MANAGING ADIPOCYTE FAT ACCUMULATION | WELLGEN, INC. (US) | 2007-03-01 | — | — | WO | claimed |
| CN-118490702-A | Citrus extract and preparation method and application thereof | 浙江大学 | 2024-08-16 | — | — | CN | disclosed |
| CN-118121589-A | Compounds and their use for inhibiting novel coronaviruses | 丰苗生物科技股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-118121649-A | Citrus extract, compound, and use thereof for inhibiting novel coronaviruses | 丰苗生物科技股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-109374762-B | Method for identifying citrus reticulata blanco and citrus reticulata blanco varieties based on metabonomics | 广州中医药大学第一附属医院 | 2021-10-08 | — | — | CN | disclosed |
| WO-2007024982-A3 | METHODS FOR MANAGING ADIPOCYTE FAT ACCUMULATION | WELLGEN INC (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070088078-A1 | Methods for managing adipocyte fat accumulation | WELLGEN, INC. | 2007-04-19 | — | — | US | disclosed |
| US-20070088078-A1 | Methods for managing adipocyte fat accumulation | WELLGEN, INC. | 2007-04-19 | — | — | US | disclosed |
| WO-2007024982-A2 | METHODS FOR MANAGING ADIPOCYTE FAT ACCUMULATION | WELLGEN, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007024982-A2 | METHODS FOR MANAGING ADIPOCYTE FAT ACCUMULATION | WELLGEN, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088078-A1 | Methods for managing adipocyte fat accumulation | FABP4, PLIN5, PLIN3 | ACHE 1967/4885PLK1 3176/4885BACE1 3161/4885 |
| US-20070275106-A1 | Hydroxylated polymethoxyflavone compositions | PLIN5, FANCF, COXFA4 | ACHE 4054/4885PLK1 1669/4885BACE1 4617/4885 |
| US-20140039044-A1 | Hydroxylated Polymethoxyflavone Compositions | PLIN5, FANCF, COXFA4 | ACHE 4054/4885PLK1 1669/4885BACE1 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.